Respiratory Diseases

Children hospitalized for RSV with LRTI during infancy have increased symptoms and lung function abnormalities, including increased resistance and decreased compliance.

Primary care clinicians will often be the first challenged to recognize neurologic sequelae of COVID-19; here's how to maximize short visits to assess long COVID.

The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.

Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.

The Pfizer vaccine RSVpreF administered to pregnant people was judged by the advisory committee to be effective at preventing RSV in infants from birth to 6 months.

Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."

New CDC recommendations for pneumococcal vaccination for persons aged 19 to 64 years could require some extra thought. This 4-question quiz tests your knowledge.

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

Results from a prospective birth cohort study show an age-dependent association between RSV infection during infancy and childhood asthma.

Your daily dose of clinical news you may have missed.

Complications were more common among patients with comorbid respiratory failure and RSV although mortality rates did not differ, report Thai investigators.

Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.

Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.

For each of the 6 biologic agents FDA-approved for severe asthma, find the mechanism of action, indication, and biomarkers that predict enhanced response.

The burden of RSV-positive acute respiratory infections in older adults during the pre-COVID-19 period was substantial, according to findings from a Mayo Clinic team.

Your daily dose of clinical news you may have missed.

In most patients with viral respiratory infections, the chance of bacterial coinfection is low and antibiotics can be withheld safely, say authors of a new study.

Adding paired serology and sputum to nasal swab/nasopharyngeal swabs RT-PCR increased RSV detection by 50% to 66% on average, respectively.

Dupilumab in patients with uncontrolled COPD reduced annual exacerbations by 30%, a statistically significant and clinically meaningful outcome and a first for a biologic.

Delivered intranasally, the fully human anti-CD3 mAb Foralumab modulated T-cell inflammation in COVID-19 and may have wider application, say study authors.

AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.

AAAAI 2023. Pandemic prescribing rates for systemic corticosteroids increased from Alpha to Delta to Omicron waves of COVID-19 but hospitalizations have dropped, study finds.

Pfizer will present pivotal phase 3 data for RSVpreF to the ACIP on February 23; FDA has set a PDUFA date for the vaccine candidate of August 2023.

Medical director of the NFID William Schaffner, MD, shares his messages to primary care clinicians as the final months of this year's flu season near.

Prediction of COPD exacerbations was significantly better with a CT biomarker-based model than either exacerbation history or BODE index.

Which states have the most residents reporting long COVID symptoms? Which ones have the least? Scroll through our new slideshow for answers.

Vaccine uptake this respiratory virus season is lagging compared to previous years, says Schaffner, medical director of the National Foundation for Infectious Diseases.